PUBLISHER: The Business Research Company | PRODUCT CODE: 1949800
PUBLISHER: The Business Research Company | PRODUCT CODE: 1949800
Autacoids and related drugs are biologically active compounds produced by the body that act locally to regulate physiological functions, usually within specific tissues or organs. They play roles in inflammation, smooth muscle contraction, immune responses, and blood flow regulation. Autacoids function by binding to specific receptors on target cells, triggering signaling pathways that affect cellular activity.
The main types of autacoids and related drugs include histamines, prostaglandins, leukotrienes, serotonin, and bradykinin. Histamines are chemicals released during allergic reactions, causing symptoms such as itching, swelling, and increased stomach acid, and are targeted in treatments for allergies and acid-related conditions. These drugs can be administered via oral, injectable, topical, intranasal, or inhalation routes. They are used for various applications, including cardiovascular disorders, inflammatory diseases, respiratory conditions, allergies, and gastrointestinal issues. The primary end users include hospitals, clinics, homecare settings, and pharmacies.
Tariffs have affected the autacoids and related drug market by increasing the cost of imported active pharmaceutical ingredients, chemical intermediates, and formulation excipients used in histamine, prostaglandin, and leukotriene drugs. These impacts have been most pronounced in cardiovascular and inflammatory disease segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have faced pricing pressures due to raw material imports. However, tariffs have encouraged domestic production of generic autacoid-based therapies.
The autacoids and related drug market research report is one of a series of new reports from The Business Research Company that provides autacoids and related drug market statistics, including autacoids and related drug industry global market size, regional shares, competitors with a autacoids and related drug market share, detailed autacoids and related drug market segments, market trends and opportunities, and any further data you may need to thrive in the autacoids and related drug industry. This autacoids and related drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The autacoids and related drug market size has grown strongly in recent years. It will grow from $52.81 billion in 2025 to $55.87 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to inflammatory disease prevalence, allergy incidence growth, cardiovascular disorder burden, gastrointestinal disorder treatments, hospital pharmacology expansion.
The autacoids and related drug market size is expected to see strong growth in the next few years. It will grow to $70.07 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to precision pharmacology adoption, receptor-targeted drug development, chronic disease management growth, outpatient treatment expansion, combination therapy usage. Major trends in the forecast period include expanding use in inflammatory disease management, increased focus on receptor-specific drug action, growing demand for targeted autacoid modulators, rising use in cardiovascular and respiratory care, increased adoption of combination therapies.
The rising prevalence of cardiovascular diseases is expected to drive the growth of the autacoids and related drugs market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. This increase is largely linked to poor dietary habits, as excessive intake of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels-key risk factors for heart-related conditions. Autacoids and related drugs support cardiovascular health by modulating vascular tone and inflammation, which is critical in conditions such as hypertension and heart failure. Agents targeting pathways involving nitric oxide, endothelin, and prostacyclin help restore endothelial function, promoting vasodilation and lowering vascular resistance. For example, in September 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported 17.9 million deaths from cardiovascular diseases. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the autacoids and related drugs market.
Leading companies in the autacoids and related drugs market are concentrating on developing innovative products, such as antihistamines, to improve therapeutic effectiveness, minimize side effects, and address emerging allergic and inflammatory conditions with greater precision and safety. Antihistamines are medications that counteract the effects of histamine, a chemical released by the immune system during allergic reactions. For example, in March 2023, Tiefenbacher Pharmaceuticals, a Germany-based pharmaceutical company, launched Bilastine as an over-the-counter (OTC) medicine in Germany, representing a significant advancement in access to effective allergy treatments. The 20 mg Bilastine tablets provide a non-sedating, second-generation antihistamine option for patients experiencing allergic symptoms such as hay fever and urticaria.
In May 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals Inc. for approximately $750 million. Through this acquisition, Incyte aims to expand its immunology portfolio and accelerate the development of novel treatments for pruritus and other inflammatory disorders by incorporating Escient Pharmaceuticals' innovative pipeline of first-in-class, small-molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs). Escient Pharmaceuticals Inc., based in the US, develops novel therapeutics focused on autacoid-related pathways.
Major companies operating in the autacoids and related drug market are Sanofi S.A., Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Limited, EUROAPI S.A., Pfizer CentreOne, Cayman Chemical Company, Tokyo Chemical Industry Co. Ltd., Avanti Polar Lipids Inc., Kyowa Pharma Chemical Co. Ltd., Nicox S.A., Glentham Life Sciences Ltd., LGM Pharma Inc., chemBlink Inc., ZellBio GmbH, AquigenBio LLC, BOC Sciences Inc., Yarrow Chem Products Pvt. Ltd., LEBSA S.A., VDK NaturaSyn S.A., Enzo Life Sciences Inc.
North America was the largest region in the autacoids and related drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autacoids and related drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the autacoids and related drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The autacoids and related drug market consists of sales of biogenic amines, polypeptide autacoids, lipid-derived autacoids, and leukotrienes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Autacoids And Related Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses autacoids and related drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for autacoids and related drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The autacoids and related drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.